AVROBIO Obtains $60 Million for Phase 2 Trial of Its Fabry Disease Gene Therapy
AVROBIO has obtained $60 million in additional financing to start a Phase 2 clinical trial of its gene therapy for Fabry disease. The second round of financing will also help the company continue developing treatments for other lysosomal storage disorders, Gaucher disease, cystinosis, and Pompe disease. A Phase 1 trial (…